IPOS Extended Its Patent Acceleration Initiatives under ASPEC AIM Programme and PPH Programme with China

The Intellectual Property Office of Singapore (IPOS) has recently extended its two pilot patent acceleration programmes such as the ASPEC Acceleration for Industry 4.0 Infrastructure and Manufacturing Pilot (ASPEC AIM) Programme until 26 August 2023, and the Patent Prosecution Highway (PPH) agreement with the China National Intellectual Property Administration (CNIPA) until 31 August 2026, in […]

Updates on Singapore patent practice

Following a series of public consultation and discussions, the Intellectual Property Office of Singapore (IPOS) has confirmed that they will launch a formal procedure for the submission of “third party observations” under which members of the public will be able notify IPOS of information that might be of relevance to the patentability of an invention […]

A second-round victory for brand drug owners against generics who fail to declare relevant patents under Singapore’s patent linkage regime

Proprietors of brand-name drugs may heave another sigh of relief as the Singapore Court of Appeal in Zyfas Medical Co (Sued as a firm) v. Millennium Pharmaceuticals, Inc [2020] SGCA 84 re-affirmed its holding in Millennium Pharmaceuticals, Inc v. Drug Houses of Australia Pte Ltd [2019] SGCA 31 (the DHA decision) rejecting an overly-restrictive interpretation […]

New Singapore Patent Fast Track Programme to Accelerate Patent Prosecution Timeframe

The Intellectual Property Office of Singapore (IPOS) in its continuing effort to expand support to innovators, launched a new programme named the “SG Patent Fast Track”  on 4 May 2020 to replace the existing patent acceleration programmes, namely FinTech Fast Track and Accelerated Initiative for Artificial Intelligence (“AI2”), which ceased on 25 April 2020 and […]

Brand Drug Owners Vindicated Against Generics Seeking to Launch Without Declaring Relevant Patents Under Patent Linkage Regime

INTRODUCTION The Singapore Court of Appeal’s judgment in Millennium Pharmaceuticals, Inc v Drug Houses of Australia Pte Ltd [2019] SGCA 31 heralds momentous change in the pharmaceutical sector for brand drug owners seeking to enforce patents against generic competitors. The Court reversed an interlocutory decision of the High Court that made it difficult for brand […]

Philippines – IPOPHL Clarifies Rules for Filing Divisional Patent Applications

On 1 September 2018, the Intellectual Property Office of the Philippines (“IPOPHL”) issued a Memorandum Circular No. 18-0031 setting out the conditions and considerations when filing a divisional patent application in the Bureau of Patents (“BOP”). According to rules 610 and 611 of the Revised Implementing Rules and Regulations2 (Revised IRR), an applicant can file […]

Patentability of Computer Related or Implemented Inventions (CRIs or CIIs) in Singapore, Indonesia, Thailand, Vietnam, Philippines, and India

Patent legislation and practice in the patentability assessment of computer related or implemented inventions differ from country to country. “Computer Related Inventions” (“CRIs”) or “Computer Implemented Inventions” (“CIIs”) has been given an explicit definition in some countries such as in Philippines and India. These countries both define CRIs or CIIs as those inventions involving computers, […]

Improvements in the India IP Scene

The US Chamber of Commerce Global Innovation Policy Center (“GIPC”) has recently released its 2018 Intellectual Property Index (“IPI”) in February 2019. India has improved on its previous 2017 position of 44 in 2017 and now ranks at number 36 out of 50 countries. Countries are ranked annually by the GIPC based on their trademark, […]